Derma Sciences' MediHoney Gel gets FDA nod
This article was originally published in Clinica
MediHoney Gel, a treatment for wounds and burns developed by Derma Sciences (Princeton, New Jersey) has gained 510(k) clearance from the US FDA. The product is based on Active Manuka (Leptospermum) honey blended with gelling agents. This is the fourth product in the MediHoney franchise, and will be launched this spring.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.